sprite-preloader
Anzeige
Mehr »
Montag, 26.06.2017 Börsentäglich über 12.000 News von 558 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Passende Knock-Outs zu Ihrer Suchanfrage (Anzeige)
Erweiterte
Suche
lynx
Ad hoc-Mitteilungen
21.04.2017 | 16:46
(3 Leser)
Schrift ändern:
(0 Bewertungen)

PR Newswire·Mehr Nachrichten von PR Newswire

DUBLIN, Apr 21, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Hepatocellular Carcinoma Drug Sales (Nexavar & Miripla), Pipeline Analysis and Global Market Forecast 2022" report to their offering.

Research and Markets Logo

The global hepatocellular carcinoma drug market is anticipated to witness a remarkable growth in the coming years. The report provides insights about the major drivers and challenges, along with the latest innovations in this industry. In addition, the report also highlights various opportunities for the growth of the Global Hepatocellular Carcinoma Market.

The report provides insights about the major drivers and challenges, along with the latest innovations in this industry. In addition, the report also highlights various opportunities for the growth of the Global Hepatocellular Carcinoma Market.

Key factors supporting the growth of the global hepatocellular carcinoma market include increasing incidences of chronic diseases like infection with hepatitis B or C virus, diabetes, obesity, non-alcoholic fatty liver diseases, and others. Moreover, the growing aging population, adoption of sedentary lifestyle, and increasing R&D investments are also adding up to the growth of global hepatocellular carcinoma market. However, drug failures in pipeline and stringent regulatory challenges are expected to hamper the growth of the global hepatocellular carcinoma drug market.

Furthermore, in this report we have structured the information regarding hepatocellular drugs at various stages of clinical development, totaling to over 350 drugs that are under research or in collaboration and those individually being developed by companies. Out of which, 102 drugs are being developed by industries and rest of the drugs are developed by the research collaborations. The report also provides the segmentation of hepatocellular carcinoma drugs under clinical development on the basis of clinical phase.

Moreover, the report also highlights various mergers and acquisitions taking place in the global hepatocellular carcinoma drug market. The last section of the report discusses about the prominent players in global hepatocellular carcinoma drug market. A brief business overview and financial information about each of these players has been provided, along with their product portfolios. The recent developments of every player have also been presented in the report. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the global hepatocellular carcinoma drug market.

Key Topics Covered:




1. Analyst View

2. Research Methodology

3. Hepatocellular Carcinoma- An Introduction

3.1 Etiology and Epidemiology of Hepatocellular Carcinoma


3.2 Risk Factors

4. Market Dynamics


4.1 Drivers


4.1.1 Rising Incidences of Chronic Liver Diseases


4.1.2 Increasing Aging Population


4.1.3 Increasing R&D Investments


4.2 Challenges


4.2.1 Unsuccessful Clinical Trials


4.2.2 Stringent Regulatory Challenges


4.3 Opportunities


4.3.1 Advancement of Cancer Drug Research


4.3.2 Personalized Drug


5. Global Hepatocellular Carcinoma Drug Market Outlook 2022


6. Global Hepatocellular Carcinoma Drug Pipeline Analysis


6.1 Hepatocellular Carcinoma Drug Pipeline by Industries


6.1.1 By Clinical Phase


6.2 Hepatocellular Carcinoma Drug Pipeline by Research and Collaborations


6.2.1 By Clinical Phase


7. Market Segment by Geography


7.1 North America


7.2 Europe


7.3 Asia Pacific


8. Company Profiles


8.1 Pfizer Inc.


8.2 Eli Lilly and Company


8.3 Alnylam Pharmaceuticals, Inc.


8.4 Exelixis, Inc.


8.5 ArQule, Inc.


8.6 Polaris Pharmaceuticals, Inc. (PPI)


8.7 Bayer AG


8.8 Teva Pharmaceutical Industries Ltd.


8.9 Bristol-Mayers Squibb


8.10 Celsion, Inc.


For more information about this report visit

http://www.researchandmarkets.com/research/6fzgf9/global


Media Contact:


Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716




© 2017 PR Newswire